News Sentiment

GILD sentiment intelligence

Gilead Sciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 129.83 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

86/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-1.1% over one week, +4.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

GILD (NASDAQ: GILD) holder plans 3,000-share common stock sale

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 86/100 classification
One-week reaction -1.1% Price digesting
Trend fit Trend inactive 4.1% over four weeks
Fair value 36.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 26
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
The Globe and Mail 3
TradingView 3
simplywall.st 3
Simply Wall St. 3
TIKR.com 3
Stock Titan 2
MarketWatch 2

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 4
Deals and strategy 3
Analyst action 3
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Stock Titan Direct company coverage

Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier

Gilead Sciences, Inc. (NASDAQ: GILD) shareholder Johanna Mercier plans to sell 3,000 common shares through Morgan Stanley Smith Barney LLC on July 15, 2026, for an aggregate value of approximately $389,757.60. These shares were acquired as performance shares on February 4, 2025.

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:38
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 GILEAD SCIENCES For: 15 July By Investing.com

This article announces the filing of Form 144 for Gilead Sciences (GILD) on July 15. The brief notification is presented without further details but is relevant for investors tracking insider transactions. Gilead Sciences' stock is also noted with a 1.28% increase.

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:25
Source
Investing.com Canada
Trefis Direct company coverage

IBB ETF Holds Fewer Bets Than You Think

The iShares Biotechnology ETF (IBB) appears diversified with 249 stocks, but its effective holdings are closer to 35 equally weighted positions due to significant concentration. The top ten holdings account for 44% of its assets, with Vertex Pharmaceuticals, Amgen, and Gilead Sci

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 16:12
Source
Trefis
24/7 Wall St. Direct company coverage

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced "death crosses" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% divid

Tone
Negative 39/100
Event
Market update
Published
15 Jul 2026 13:10
Source
24/7 Wall St.
Simply Wall Street Direct company coverage

Should Gilead’s Revenue Beat but Softer EPS Outlook Require Action From Gilead Sciences (GILD) Investors?

Gilead Sciences reported a Q3 revenue beat of US$6.96 billion, exceeding analysts' expectations by 1.5%, but concurrently issued a softer full-year earnings-per-share outlook. This outcome suggests that while sales are strong, the company faces challenges in translating this grow

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 04:10
Source
Simply Wall Street
MarketWatch Direct company coverage

Gilead Sciences Inc. stock outperforms competitors despite losses on the day

Shares of Gilead Sciences Inc. (GILD) closed down 1.04% at $130.04, despite an overall positive trading session for the broader market with both the S&P 500 and Dow Jones Industrial Average seeing gains. The company's stock is currently trading 17.32% below its 52-week high of $1

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 16:35
Source
MarketWatch
Reuters Direct company coverage

Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo

Researchers in the Democratic Republic of Congo have initiated a trial for Gilead Sciences' experimental antiviral, obeldesivir, to be used as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak. The study, aimed at reducing the risk of Ebola infection after conta

Tone
Positive 71/100
Event
Market update
Published
14 Jul 2026 12:48
Source
Reuters
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD)

This article highlights bullish sentiments from financial analysts regarding three healthcare companies: Medtronic (MDT), Quest Diagnostics (DGX), and Gilead Sciences (GILD). Analysts from Bank of America Securities maintained Buy ratings for all three, setting price targets that

Tone
Positive 86/100
Event
Market update
Published
14 Jul 2026 11:27
Source
The Globe and Mail
TradingView Direct company coverage

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1

This article analyzes the Q1 performance of Gilead Sciences and other key players in the therapeutics industry. While the sector generally performed well, with revenues beating estimates and share prices rising, individual companies showed varied results. Gilead Sciences reported

Tone
Negative 38/100
Event
Earnings
Published
14 Jul 2026 03:08
Source
TradingView
The National Law Review Direct company coverage

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

Gilead Sciences, Inc. has announced that it has received all necessary regulatory approvals for its acquisition of Arcellx and has extended the tender offer for all outstanding shares of Arcellx common stock. The Australian Competition and Consumer Commission (ACCC) approved the

Tone
Positive 67/100
Event
Deals and strategy
Published
14 Jul 2026 01:44
Source
The National Law Review
Quartr Direct company coverage

Gilead Sciences (GILD) AGM 2026 Summary

The Gilead Sciences (GILD) AGM 2026 summary details the meeting's agenda, including the re-election of all nine director nominees. The board opposed shareholder proposals concerning an independent board chair, a report on patent exclusivity impact on patient access, and a report

Tone
Positive 61/100
Event
Market update
Published
13 Jul 2026 17:07
Source
Quartr
MarketWatch Direct company coverage

Gilead Sciences Inc. stock outperforms competitors on strong trading day

Gilead Sciences Inc. (GILD) saw its stock advance 1.21% to $131.40 on Monday, outperforming the broader market which experienced declines. The S&P 500 Index fell 0.79%, and the Dow Jones Industrial Average dropped 0.26% on the same trading day. This rise for Gilead Sciences Inc.

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 16:35
Source
MarketWatch
TradingView Direct company coverage

ETFs Investing in Gilead Sciences, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold shares of Gilead Sciences, Inc. (1GILD). The list details each ETF's market value, weight of Gilead stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, an

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 10:37
Source
TradingView
The Globe and Mail Direct company coverage

Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)

Wells Fargo analyst Mohit Bansal has reiterated a Buy rating for Gilead Sciences (GILD) with a $165.00 price target. This comes after Gilead reported quarterly revenue of $6.96 billion and a net profit of $2.02 billion, exceeding the previous year's figures. JPMorgan also issued

Tone
Positive 71/100
Event
Analyst action
Published
11 Jul 2026 10:25
Source
The Globe and Mail
Moomoo Direct company coverage

Gilead Sciences Down Over 4%, on Pace for Largest Percent Decrease Since July 2025 -- Data Talk

Gilead Sciences is experiencing a significant stock decrease, down over 4% today. This puts the company on track for its largest single-day percentage decrease since July 2025, indicating a notable market reaction to recent events or news concerning the biopharmaceutical firm.

Tone
Negative 30/100
Event
Market update
Published
11 Jul 2026 06:07
Source
Moomoo
Market source Direct company coverage

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Gilead Sciences (GILD) stock declined 3.72% in its latest trading session while the broader market saw gains. Despite this daily dip, GILD's stock has outperformed both the Medical sector and the S&P 500 over the past month. Investors are awaiting Gilead's upcoming earnings repor

Tone
Negative 39/100
Event
Earnings
Published
10 Jul 2026 21:37
Source
Market source
GuruFocus Direct company coverage

A Look at Gilead Sciences Inc (GILD) After 3.7% Decline -- GF Value $96.09 vs Price $129.83

Gilead Sciences Inc (GILD) shares dropped 3.7% today, with its current price of $129.83 significantly exceeding its GF Value™ of $96.09, indicating it is 35.1% overvalued. The stock's GF Score™ of 69/100 suggests above-average performance, but recent insider selling of $10.8 mill

Tone
Negative 28/100
Event
Market update
Published
10 Jul 2026 21:22
Source
GuruFocus
MSN Direct company coverage

Gilead Sciences Inc. stock underperforms Friday when compared to competitors

The article states that Gilead Sciences Inc. (GILD) stock underperformed on Friday compared to its competitors. No specific financial data for Gilead or its peers is provided in the very brief article.

Tone
Negative 30/100
Event
Market update
Published
10 Jul 2026 20:42
Source
MSN
Seeking Alpha Direct company coverage

Lakefront draws Equal Weight rating at Morgan Stanley (LKFT)

Morgan Stanley has resumed coverage of Lakefront Biotherapeutics (LKFT) with an "Equal Weight" rating and a $30 price target. This re-initiates coverage after Lakefront's acquisition of Ouro Medicines in June. The $1.7 billion deal was partly funded by Gilead.

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 17:08
Source
Seeking Alpha
TradingKey Direct company coverage

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement

Gilead Sciences Inc (GILD) stock fell by 3.26% on July 10, primarily due to the failure of a Phase 3 solid tumor clinical trial and broader macroeconomic pressures. Strong employment data contributed to increased Treasury yields, negatively impacting biotech valuations. Analysts

Tone
Negative 26/100
Event
Market update
Published
10 Jul 2026 16:14
Source
TradingKey